UK Patients to Access First-Ever Export of Australian Medicinal Cannabis Oil
15 April 2020 - 10:42PM
Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA 2LQA)
(“
ELIXXER” or (the “
Company”) is
pleased to update that its pharmaceutical medical cannabis partner,
Little Green Pharma (ASX:LGP) of Australia, has successfully
exported their first shipment of medicinal cannabis products for
patients into the UK.
The products are to be distributed in the UK by
Astral Health, a UK-based specialist importer and distributor of
medicinal cannabis products and subsidiary of the LYPHE Group. The
products were imported under the purchase agreement between the
Company and Astral Health previously announced to the ASX on 19
February 2020.
On 2 March 2020, the UK Home Office and MHRA
announced that import permits may now be granted based on
anticipated prescription quantities. This announcement sees
improvements made to the access pathway for medicinal cannabis,
increasing the efficiency of the process of exporting products to
the UK.
LGP Managing Director Fleta Solomon said:
“Little Green Pharma is one of a few companies
with GMP-produced cannabinoid medicines available in the UK. We are
proud to be leading the charge in helping patients across the globe
access quality Australian medicinal cannabis products.”
Australia’s Minister for Health, the Honourable
Greg Hunt said:
“This first export of Australian-produced
medicinal cannabis oils to the UK marks an important step in
fulfilling Australia’s vision of building a global medicinal
cannabis industry capable of supplying quality medicinal cannabis
products to both Australian and overseas patients.”
The UK industry is forecast to grow to £$1.05 billion (A$2.10
billion) by 2024, with an expected 400,000 patients being
prescribed medicinal cannabis
About Elixxer Ltd. (www.Elixxer.com)
ELXR Ltd. is a Canadian public company listed on
the TSX Venture Exchange (TSX-V: ELXR) and the US OTC-QB exchange
(OTCQB: ELIXF). Through its partners ELXR presently has significant
interests in Australia, Jamaica, Switzerland, Italy and Canada.
About Little Green Pharma
(www.littlegreenpharma.com)
Little Green Pharma is a vertically integrated medicinal
cannabis business with operations from cultivation and production
through to manufacturing and distribution.
The Company has an indoor cultivation facility in Western
Australia and an exclusive partnership with a GMP- licensed
pharmaceutical manufacturer for the production of its own-branded
range of medicinal cannabis products.
Little Green Pharma products comply with all required
Therapeutic Goods Administration regulations and testing
requirements. With a growing range of products containing differing
ratios of active ingredients, Little Green Pharma supplies
medical-grade cannabis products to Australian and overseas
markets.
The Company has a strong focus on patient access in the emerging
global medicinal cannabis market and is actively engaged in
promoting education and outreach programs, as well as participating
in clinical investigations and research projects to develop
innovative new delivery systems.
For further information please
contact:
President, John McMullen, +1-416-803-0698,
john@elixxer.com
Caution Regarding Press
Releases
Neither the TSX Venture Exchange nor its
Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Notice Regarding Forward Looking
Statements
This press release may contain forward-looking
statements with respect to Elixxer and its operations, strategy,
investments, financial performance and condition. These statements
can generally be identified by use of forward-looking words such as
“may”, “will”, “expect”, “estimate”, “anticipate”, “intends”,
“believe” or “continue” or the negative thereof or similar
variations. The actual results and performance of Elixxer,
including completion of the Loan and any future investment or
acquisition, could differ materially from those expressed or
implied by such statements. Such statements are qualified in their
entirety by the inherent risks and uncertainties surrounding future
expectations. Some important factors that could cause actual
results to differ materially from expectations include, among other
things, general economic and market factors, competition,
government regulation and the factors described under “Risk Factors
and Risk Management” in Elixxer’s most recent Management’s
Discussion and Analysis filed on SEDAR (www.sedar.com). The
cautionary statements qualify all forward-looking statements
attributable to Elixxer and persons acting on its behalf. Unless
otherwise stated, all forward-looking statements speak only as of
the date of this press release, and Elixxer has no obligation to
update such statements, except to the extent required by applicable
securities laws.
________________________
- "Prohibition Partners, The UK Cannabis Report, p 14 - 46
Elixxer (TSXV:ELXR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Elixxer (TSXV:ELXR)
Historical Stock Chart
From Aug 2023 to Aug 2024